OraSure Technologies, Inc. (OSUR)
Chart Events
Performance Outlook
| Previous Close | 9.48 |
| Open | 9.43 |
| Bid | 9.01 x 2200 |
| Ask | 9.38 x 800 |
| Day's Range | 9.29 - 9.54 |
| 52 Week Range | 8.58 - 19.75 |
| Volume | 1,184,387 |
| Avg. Volume | 868,552 |
| Market Cap | 679.971M |
| Beta (5Y Monthly) | -0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings Date | Aug 03, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.08 |
- GlobeNewswire
OraSure Technologies to Present at the Raymond James 2021 Human Health and Innovation Conference
BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a fireside chat at the Raymond James 2021 Human Health Innovation Conference. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on June 23, 2021, at 11:20 A
- GlobeNewswire
OraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing
Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease StatusBETHLEHEM, Pa. and HUNTERSVILLE, N.C., June 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it is collaborating with the Will Rodgers Liver Health Foundation to increase awareness around the role Hepatitis C (HCV) plays in chronic liver disease and promoting testing services for HCV within the United States. The U.S. Centers for Disease Control estimat
- Benzinga
OraSure's COVID-19 Rapid Antigen Tests Gets FDA Emergency Approval for OTC, Professional, Prescription Use
OraSure Technologies Inc (NASDAQ: OSUR) has received FDA Emergency Use Authorization (EUA) for its COVID-19 rapid antigen tests, InteliSwab. These tests detect active COVID-19 infection; the agency has given the emergency nod for Over-the-Counter use. FDA has also authorized the InteliSwab COVID-19 Rapid Test Pro for professional use in point of care (POC) and InteliSwab COVID-19 Rapid Test Rx for Prescription Home Use. InteliSwab incorporates a built-in swab that is fully integrated into the te
